Pulling SEC filings + quote and writing the call…

Rezolute, Inc.
Next earnings Sep 15, 2026 (after close) · consensus $-0.16 EPS
Last earnings +4.1% on 2026-05-12
Conservative balance sheet (liabilities/equity 0.08x).
Rezolute, Inc. shows limited reported revenue, and -45.9% ROE.
Sources: SEC EDGAR (CIK 0001509261, latest 10-Q filed 2026-05-12) · EODHD · as of 6/24/2026, 8:16:43 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$22.9M | -$41.8M | -$56.0M | -$70.4M | -$79.9M |
| Net income | -$20.9M | -$41.1M | -$51.8M | -$68.5M | -$74.4M |
| Diluted EPS | -$2.72 | -$2.32 | -$1.01 | -$1.33 | -$0.98 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Last 90 days: 1 open-market buy · 0 sales
| 2026-03-30 | Evans Daron CFO | Buy | 10.0K @ $2.85 | $28.5K |
| 2026-03-02 | ROBERTS BRIAN KENNETH Chief Medical Officer | Tax | 11.4K @ $2.99 | $34.2K |
| 2026-03-02 | Evans Daron CFO | Tax | 11.4K @ $2.99 | $34.2K |
| 2026-03-02 | Elam Nevan C CEO | Tax | 27.6K @ $2.99 | $82.6K |
| 2025-12-16 | Hogenhuis Wladimir Director | Buy | 5.65K @ $1.69 | $9.55K |
| 2025-12-16 | ROBERTS BRIAN KENNETH Chief Medical Officer | Buy | 28.0K @ $1.70 | $47.6K |
| 2025-12-15 | Evans Daron CFO | Buy | 40.0K @ $1.77 | $70.6K |
| 2025-12-15 | Evans Daron CFO | Buy | 2.50K @ $1.79 | $4.46K |
| 2025-12-15 | Evans Daron CFO | Buy | 2.50K @ $1.79 | $4.47K |
| 2025-12-15 | Elam Nevan C CEO | Buy | 32.0K @ $1.59 | $50.9K |